Chinese drug maker seeks NYSE listing

The company banks on an ageing Chinese population and higher urban wealth to drive growth of its key drug.

Tongjitang Chinese Medicines, which owns one of ChinaÆs most well-known pharmaceutical brands, is on the road trying to drum up interest for an initial public offering. Its plan to raise up to $168 million on the New York Stock Exchange may have become a little harder to achieve following the sharp correction in global equity markets this week.

However, people involved with the offering argue that the companyÆs fast growth rate, its focus on the elderly as its primary patient...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: ipo | nyse | pharmaceuticals | merrill lynch | ubs

Print Edition

FinanceAsia Print Edition